Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

Hereditary Cancer in Clinical Practice
Wiktor SzatkowskiTomasz Byrski

Abstract

Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2 germline mutation than for patients with sporadic OC. However, most published data are for North American, British and Jewish populations. There have been very few studies on treatment outcomes in Central and Eastern European patients with OC. The aim of this study was to analyse prognostic factors in Polish patients with BRCA1-dependent OC (BRCA1-OC). The records of patients with OC treated with surgery and chemotherapy at the Centre of Oncology in Kraków, Poland, between 2004 and 2009 were reviewed. Based on family history, a group of 249 consecutive patients fulfilling the criteria for risk of hereditary OC were selected and tested for the germline BRCA1 mutation. Response to combination therapy (surgery and chemotherapy) in the BRCA1-OC group was assessed based on clinical examination, imaging and serum CA125. Germline BRCA1 mutations were detected in 69 of the 249 patients, but three of these patients failed to complete the study. Finally, 66 patients with BRCA1-OC were included in the study group. The median age of the study patients was 49.5 years. All had undergone primary or interval cytoreductive surgery and chemotherapy. Prog...Continue Reading

References

Mar 1, 1987·Gynecologic Oncology·R D AlvarezM E Potter
Nov 7, 1996·The New England Journal of Medicine·S C RubinJ Boyd
May 18, 1999·Gynecologic Oncology·A R JeyarajahI J Jacobs
May 12, 2000·JAMA : the Journal of the American Medical Association·J BoydW J Hoskins
May 25, 2001·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·S J RamusB A Ponder
Apr 25, 2003·Cancer·Ilana CassBeth Y Karlan
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela ChetritSiegal Sadetzki
Oct 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David S P TanMartin E Gore
Mar 23, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Liz Y HanStan B Kaye
Nov 19, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D J GallagherN D Kauff
Jan 26, 2012·JAMA : the Journal of the American Medical Association·Kelly L BoltonUNKNOWN Cancer Genome Atlas Research Network
Apr 2, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P M L H VenckenC Seynaeve

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.